News
-
De Simone Formulation Named in AGA Clinical Practice Guidelines on Management of Pouchitis and Inflammatory Pouch Disorders
By: Jenna Sheldon, DO, MS Pouchitis is an inflammatory condition that may occur in patients who have undergone an ileal pouch anal anastomosis (IP... -
ExeGi Pharma Announces First Patient Enrollment in the PROF Trial of EXE-346
ROCKVILLE, MD – ExeGi Pharma, a pioneering biopharmaceutical company dedicated to the development and commercialization of innovative live biother... -
ExeGi Pharma Announces Launch of Visbiome Vet Constipation Care: A Breakthrough Probiotic Product for Occasional Constipation in Cats
Rockville, MD – ExeGi Pharma, leaders in therapeutic probiotic solutions, today unveiled Visbiome Vet Constipation Care, a revolutionary probiotic... -
Visbiome GI Care High Potency Capsules Now Certified by the Clean Label Project®
Rockville, MD – ExeGi Pharma LLC, a leader in digestive health solutions, is proud to announce that its flagship product, Visbiome GI Care Probioti... -
ExeGi Pharma Announces Partnership with TannerLAC to Bring Visbiome® High Potency Probiotic to Mexico
Visbiome® is a high potency probiotic medical food designed to manage microbial imbalances associated with medical conditions such as irritable bowel syndrome (IBS), Ulcerative Colitis (UC), Antibiotic-Associated Diarrhea (AAD), Pouchitis, and Hepatic Encephalopathy (HE). With a proven track record in over 80 human clinical trials performed over the past 20 years, Visbiome® is the most extensively researched multi-strain probiotic available. -
Visbiome Probiotic Prevails in Landmark False Advertising Lawsuit Against Competitor Brookfield Pharmaceuticals
April 5, 2023 – ExeGi Pharma, LLC, owner of the Visbiome probiotic, has secured a significant legal victory against Brookfield Pharmaceuticals, LLC... -
New Study Finds Visbiome® High Potency Probiotic May Decrease Depressive Symptoms in Depressed Patients
Novel study evaluates the microbiota-gut-brain axis as a pathway to supportive care in mental health challenges June 8, 2022 (Rockville, MD) – A n... -
Appeals Court Upholds False Advertising Verdict Against Sellers of VSL#3® Probiotic
ExeGi Pharma LLC, the makers of Visbiome, announced today that the United State Court of Appeals for the Fourth Circuit has upheld a prior $15 million jury verdict in which the sellers of the VSL#3® probiotic were found liable for false advertising. -
New Study Finds Visbiome High Potency Probiotic May Benefit Some Autistic Children
October 15, 2020 (Rockville, Maryland) – A new study published in the peer-reviewed journal Frontiers in Psychiatry finds the high-potency De Sim... -
ExeGi Pharma Announces FDA Orphan Drug Designation for EXE-346 Live Biotherapeutic
November 12, 2020 (Rockville, Maryland): ExeGi Pharma LLC, a company focused on developing live biotherapeutic ("LBP") drugs and probiotics, announ... -
Stocking Up? Visbiome Lasts 24 Months Refrigerated
COVID-19 continues to cause nationwide shutdowns and quarantines, and the timeline regarding a return to normalcy remains uncertain. Because even o...
- Page 1 of 2
- Next page